Imiglucerase

Summary

Imiglucerase (CHEMBL1201632) is an approved enzyme (ATC A16AB02); indicated across 5 conditions including gaucher disease and thrombocytopenia.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Enzyme
• ATC class: A16AB02
• Indications: 5 conditions
• Clinical trials: 9

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201632
Name	Imiglucerase
Type	Enzyme
Max phase	4
ATC	A16AB02

Also known as: Abcertin, Cerezyme, Imiglucerasa, Imiglucerase, Isu abxis, Isu-302, IMIGLUCERASE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (5 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
Gaucher disease	4	MONDO:0018150	Orphanet:77259
thrombocytopenia	4	MONDO:0002049	HP:0001873
anemia	4	MONDO:0002280	MONDO:0002280

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
PHASE3	4
PHASE4	2
PHASE2	1
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00364858	PHASE4	COMPLETED	Safety and Efficacy of Cerezyme® Infusions Every 4 Weeks Versus Every 2 Weeks in Type 1 Gaucher Disease
NCT04656600	PHASE4	COMPLETED	Study to Evaluate Efficacy and Safety of Imiglucerase Treatment in Chinese Patients With Gaucher Disease Type Ⅲ
NCT05222906	PHASE3	ACTIVE_NOT_RECRUITING	Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3
NCT00553631	PHASE3	COMPLETED	Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease
NCT00943111	PHASE3	COMPLETED	A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)
NCT03485677	PHASE3	COMPLETED	Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3
NCT02843035	PHASE2	ACTIVE_NOT_RECRUITING	Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension
NCT04787887	PHASE1	COMPLETED	A Phase I Study to Compare Abcertin and EU-sourced Cerezyme® in Healthy Volunteers
NCT01136304	Not specified	COMPLETED	Validating a New Severity Score System for Adults With Type 1 Gaucher Disease (GD1)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).